Skip to main content

Table 2 Availability of anti-malarials and malaria testing among anti-malarial stocking private sector outlets

From: The malaria testing and treatment landscape in mainland Tanzania, 2016

  Private for-profit facility % CI Pharmacy % CI ADDO % CI DLDB % CI Private sector total % CI
N=118 N=60 N=1468 N=142 N=1800
QA ACT 73.6 (63.0, 82.0) 90.0 (75.0, 96.4) 66.3 (57.7, 74.0) 58.8 (42.8, 73.1) 65.1 (57.2, 72.3)
Non-QA ACT 66.5 (49.0, 80.4) 98.7 (94.2, 99.7) 43.3 (33.1, 54.1) 34.9 (21.3, 51.4) 42.9 (31.5, 55.1)
SP 76.8 (70.0, 82.4) 94.4 (90.2, 96.9) 92.2 (87.9, 95.0) 75.2 (62.2, 84.9) 86.3 (80.4, 90.6)
Oral quinine 63.9 (49.0, 76.6) 74.8 (61.7, 84.5) 65.2 (57.7, 72.1) 67.8 (51.5, 80.6) 64.6 (57.9, 70.8)
Other non-artemisinin therapy 8.1 (3.9, 16.2) 0.7 (0.1, 3.4) 2.6 (1.3, 5.3) 6.1 (2.6, 14.0) 4.0 (2.3, 7.0)
IV/IM artesunate 34.4 (26.9, 42.9) 17.9 (5.6, 44.5) 0.2 (0.1, 0.8) 0.0 (–) 2.4 (1.4, 4.0)
  N=120 N=61 N=1490 N=146 N=1832
Any test 96.0 (91.1, 98.3) 21.9 (12.8, 34.8) 10.2 (6.4, 15.9) 8.1 (3.9, 16.2) 15.7 (12.6, 19.4)
Microscopy 73.9 (51.0, 88.5) 8.8 (1.8, 34.3) 0.6 (0.2, 2.3) 0.0 (–) 5.4 (2.8, 10.3)
RDT 78.5 (69.4, 85.4) 21.9 (12.8, 34.8) 9.7 (6.0, 15.3) 8.1 (3.9, 16.2) 14.3 (11.4, 17.7)